Introduction {#s1}
============

MicroRNAs are a class of small non-coding RNAs approximately 21 nucleotides in length, which regulate about 30% of human genes at post-transcription level and subsequently affect the biological processes of cells. They have been identified to repress the translations and/or promote the degradations of their target mRNAs by specifically binding to the 3′ untranslated regions of the mRNAs [@pone.0089223-Sand1]. Plenty of works have confirmed the significant role of miRNAs in regulating cell proliferation, differentiation, apoptosis, metabolism, development and immunity since their first discovery in 1993 [@pone.0089223-Lee1].

In 2002, a research depicted a decreased expression of miRNA-15a and miRNA-16-1 in B-cell chronic lymphocytic leukemia, which was the first evidence of an association between miRNA and cancer [@pone.0089223-Calin1]. After that, different groups described the expression profiles of miRNA in various types of cancers [@pone.0089223-Calin2]. Now it's widely accepted that miRNAs function as cancer suppressors or oncogenes.

MiR-210 is a well-known hypoxia-inducible miRNA that expressed in a wide range of cells. It's a key factor involving in cell proliferation, mitochondrial respiration, DNA repair, vascular biology and angiogenesis [@pone.0089223-Chan1]. Since 2007 [@pone.0089223-Kulshreshtha1], [@pone.0089223-Szafranska1], a host of works have showed the prognosis effect of miR-210 on different cancers, such as breast cancer [@pone.0089223-Camps1], epithelial ovarian cancer [@pone.0089223-Giannakakis1], diffuse large B-cell lymphoma [@pone.0089223-Lawrie1], lung cancers [@pone.0089223-Duncavage1], pancreatic adenocarcinomas [@pone.0089223-Ho1], kidney cancers [@pone.0089223-Juan1] and so on. Most of the researches revealed an elevated expression of miR-210 in cancer tissues compared with normal tissues, and which is related to a poor survival outcome [@pone.0089223-Camps1], [@pone.0089223-Duncavage1], [@pone.0089223-Gee1], [@pone.0089223-Ho2], [@pone.0089223-Zhao1], [@pone.0089223-Rothe1], [@pone.0089223-Lorenzen1], [@pone.0089223-Toyama1], [@pone.0089223-Qiu1], [@pone.0089223-Wotschofsky1]. However, there were still reports showing the insignificant or opposite results [@pone.0089223-Camps1], [@pone.0089223-Giannakakis1], [@pone.0089223-Lawrie1], [@pone.0089223-Gee1], [@pone.0089223-McCormick1], [@pone.0089223-Greither1], [@pone.0089223-Zaravinos1]. Therefore, it is essentially necessary to carry out a systematic review and meta-analysis to summarize the published global findings, and get a better understanding on the significance of miR-210 expression in the prognosis of cancer patients.

In the current study, global related literatures were collected to conduct a systematic review and meta-analysis, and the risk of increased miR-210 expression to the survival of cancer patients was successfully assessed.

Materials and Methods {#s2}
=====================

This meta-analysis was conducted totally following the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2009 Checklist (<http://www.prisma-statement.org/statement.htm>) and Meta-analysis of Observational Studies in Epidemiology group (MOOSE) [@pone.0089223-Stroup1]. The PRISMA 2009 Checklist and MOOSE Checklist for our study are shown in supplementary materials ([Checklist S1](#pone.0089223.s003){ref-type="supplementary-material"} and [Checklist S2](#pone.0089223.s004){ref-type="supplementary-material"}).

Identification of Eligible Studies {#s2a}
----------------------------------

We systematically and carefully searched the online Pubmed (<http://www.ncbi.nlm.nih.gov/pubmed>) and Embase (<http://www.embase.com/home>) from 1993 to December 4th, 2013 to collect related literatures, using "miR-210 and cancer", "miR-210 and carcinoma", "miR-210 and tumor", "miR-210 and neoplasm" as keywords respectively. We set no advanced limitations when searching the both databases. All the searching results were checked by going through the titles and abstracts. The duplications were removed directly. Records were eligible if they met the following criteria: (i) they studied patients with any type of carcinoma; (ii) they measured the expression of miR-210 in cancer tissue or serum; and (iii) they investigated the relationship between miR-210 expression level and survival outcome.

Articles were excluded according to the following criteria: (i) reviews, comments, conference abstracts, letters or laboratory studies, (ii) with only the expression of a set of miRNAs other than a separated one, (iii) lack of key information or cannot estimate HR by the shown data.

In case of multiple reports on the same trial, we selected the one with more details for meta-analysis. The references of the selected reports were also checked for any possible eligible studies. As to articles without essential data, we sent request to the authors by E-mail, and only qualified the one with enough provided data.

Information of the eligible reports, such as titles, abstracts and full texts was independently and carefully identified by three reviewers (Wang, Shi and Ding). Zhao and Sun checked these extracted articles for a second time. These reviewers (Wang, Shi, Ding, Zhao and Sun) discussed to resolve any disagreement or consulted with senior reviewers (Zou and Yuan).

Quality Assessment {#s2b}
------------------

All the included studies were evaluated according to the critical review checklist of the Dutch Cochrane Centre proposed by MOOSE [@pone.0089223-Stroup1]. The key points were as following: (i) enough information of study population, (ii) enough information of the carcinoma, (iii) clear description of study design, (iv) clear description of outcome assessment, (v) enough description of miR-210 measurement, (vi) clear description of cut-off of miR-210 and (vii) sufficient period of follow-up. We excluded the studies without mentioning all these seven points.

Data Extraction and Conversion {#s2c}
------------------------------

Data were extracted independently in standardized data-collection forms. The extracted data included the following details: (i) publication information: first author's last name and publication year; (ii) patients' characteristics: sample size, disease, stage of disease, histological type and follow-up; (iii) miR-210 measurement and cut-off value; and (iv) HR of elevated miR-210 for overall survival (OS), recurrence-free survival (RFS), progress-free survival (PFS), disease-free survival (DFS), as well as their 95% confidence intervals (CI) and *P* values. If available, the HRs with their 95% CIs and *P* values were collected from the original article or the corresponding E-mails. If not, we calculated HRs and their 95% CIs using the data of observed deaths/cancer recurrences, the data of samples in each group or the data provided by the authors. If only Kaplan--Meier curves were available, we extracted data from the graphical survival plots and estimated the HRs. All the calculations mentioned above were based on the methods provided by Parmar, M. K. et al [@pone.0089223-Parmar1] and Tierney, J. F. et al [@pone.0089223-Tierney1].

Statistical Analysis {#s2d}
--------------------

The test of heterogeneity of combined HRs was carried out using Cochran's Q test and Higgins I-squared statistic. A *P* value of \<0.05 and/or I^2^\>50% was considered statistically significant. A random effect model (Der Simonian and Laird method) was applied if heterogeneity was observed, while a fixed effect model was used in the absence of between-study heterogeneity (*P*≥0.05, I^2^≤50%). The factors contributed to heterogeneities were analyzed by sub-group analysis, meta regression or sensitive analysis. Publication bias was evaluated using the funnel plot with the Egger's bias indicator test [@pone.0089223-Egger1]. All analyses were performed using 'STATA: Data Analysis and Statistical Software' V11.

Results {#s3}
=======

Study Characteristics {#s3a}
---------------------

We collected 449 records from Pubmed and 1253 from Embase in the primary search, and excluded 1283 duplicates from the initial 1702 records. After screening the titles, abstracts, publication types and full texts of the rest 419 records, 17 records were qualified for the present study. Then, the references of these qualified records were manually checked and 1 additional record [@pone.0089223-Volinia1] was found and included. Two articles showing only the conclusion without essential data were excluded. Finally, we got 16 records for systematic review and meta-analysis [@pone.0089223-Camps1], [@pone.0089223-Gee1], [@pone.0089223-Rothe1], [@pone.0089223-Toyama1], [@pone.0089223-Qiu1], [@pone.0089223-McCormick1], [@pone.0089223-Greither1], [@pone.0089223-Zaravinos1], [@pone.0089223-Volinia1], [@pone.0089223-Greither2], [@pone.0089223-Neal1], [@pone.0089223-Radojicic1], [@pone.0089223-Madhavan1], [@pone.0089223-Cai1], [@pone.0089223-Wotschofsky2], [@pone.0089223-Markou1]. [Fig. 1](#pone-0089223-g001){ref-type="fig"} showed the flow diagram of candidate study selection in our study.

![The flowchart showed the selection of studies for meta-analysis.](pone.0089223.g001){#pone-0089223-g001}

The main information of the 16 articles was summarized in [Table 1](#pone-0089223-t001){ref-type="table"}. All of the 16 articles were retrospective in design. The collected 1809 patients were from the United Kingdom, Germany, Australia, Greece, Japan, China and the United States. The patients were diagnosed with a variety of cancers, including breast cancer, primary head and neck squamous cell carcinoma (HNSCC), renal cancer, soft-tissue sarcoma, pediatric osteosarcoma, bladder cancer and glioblastoma. Of all the studies, 7 were focused on breast cancer (n = 955) [@pone.0089223-Camps1], [@pone.0089223-Rothe1], [@pone.0089223-Toyama1], [@pone.0089223-Volinia1], [@pone.0089223-Radojicic1], [@pone.0089223-Madhavan1], [@pone.0089223-Markou1], 3 on renal cancer (n = 182) [@pone.0089223-McCormick1], [@pone.0089223-Neal1], [@pone.0089223-Wotschofsky2] and 2 on sarcoma (n = 546) [@pone.0089223-Greither1], [@pone.0089223-Cai1]. Fourteen of the 16 studies assessed miR-210 expression by quantitative PCR, a widely used method for miRNA quantitation. All studies measured miR-210 expression in collected tumor samples except one research in serum [@pone.0089223-Madhavan1]. Even most researches preferred mean/media as cut-off values, there were still records using tercentiles [@pone.0089223-Toyama1], [@pone.0089223-Greither1], quartile [@pone.0089223-Camps1], [@pone.0089223-Gee1], [@pone.0089223-Madhavan1] or maximum normal tissue expression value [@pone.0089223-Neal1] instead. The follow-up time ranged from 20 months to 180 months, and reached more than 100 months in 11 researches. All the HRs and their 95% CIs in the collected articles were shown in [Table 2](#pone-0089223-t002){ref-type="table"}. We carefully summarized all the available assay details in [Table 3](#pone-0089223-t003){ref-type="table"}. Firstly, except 2 researches mentioned nothing about their internal references, 7 researches used 1 molecular as their internal references, 3 researches used 2 and 4 researches used 3. Secondly, 6 researches were lack of the information of expression analysis method, 7 researches used ΔΔCt, 1 used Cp value, 1 used Cq value, and 1 used ΔΔCq value. Thirdly, the expressions of miR-210 were quite different from each other. Two researches did not supply the expression levels of miR-210, 1 research only listed the *P* value, 7 researches used fold changes as the expression level of miR-210, and the rest 6 researches showed the miR-210 expression level normalized to their internal references. As to the risk evaluation methods, 2 researches used univariate regression, 10 researches used Kaplan-Meier curves and the rest 4 used Multiple Cox proportional harzard model.

10.1371/journal.pone.0089223.t001

###### Summary table of meta-analysis.

![](pone.0089223.t001){#pone-0089223-t001-1}

                      origin ofpopulation   studydesign             diseases              N =     Stage     miR-210assay                  cut-off                            survivalanalysis             Hazard ratios           follow-upmonths
  ------------------ --------------------- ------------- ------------------------------- ------ ---------- -------------- --------------------------------------- -------------------------------------- --------------- ----------------------------------
  Cai, 2013                  China               R           pediatric osteosarcoma        92       --        qRT-PCR                     median                                 OS, PFS                    reported                82 (10--133)
  Camps, 2008                 UK                 R                breast cancer           219     I--III      qRT-PCR                median/quartiles                            OS, DFS                    reported                    120
  Gee, 2009                   UK                 R                primary HNSCC            46     I--IV       qRT-PCR                median/quartiles                            OS, RFS                    AP/DE/SC      clinical 41(1--53);DFS 40(2--53)
  Greither,2009             Germany              R                    PDAC                 56       --        qRT-PCR                     median                                 OS, DFS                   reported/DE              15.99(1--61)
  Greither,2012             Germany              R             soft-tissue sarcoma         78     I--IV       qRT-PCR                   tercentiles                                DSS                         AP                       120
  Madhavan, 2012            Germany              R          metastatic breast cancer      269       --        qRT-PCR                 lower quartile                             OS, PFS                       SC                        20
  Markou,2013               Greece               R                breast cancer           112     I--III      qRT-PCR                     median                                  OS,DFS                    reported                   148.8
  McCormick, 2012             UK                 R                renal cancer             40     T1--T3      qRT-PCR                     median                                    OS                         SC                       120
  Neal, 2010               Australia             R                renal cancer             31    pT1--pT4     qRT-PCR      maximum normal tissueexpression value                    OS                         SC                       140
  Qiu, 2013                  China               R                glioblastoma            458       --        qRT-PCR                     median                                 OS, PFS                       SC                       130
  Radojicic, 2011           Greece               R                breast cancer            49       --        qRT-PCR                      mean                                  OS, DFS                    AP/DE/SC                    116
  Rothe, 2011                 UK                 R                breast cancer            73     I--III      qRT-PCR                     median                                   RFS                      reported                    120
  Toyama, 2012               Japan               R        triple-negative breast cancer    40     I--III      qRT-PCR                   tercentiles                DFS[\*](#nt102){ref-type="table-fn"}     reported                    168
  Volinia, 2012               USA                R                breast cancer            58       --        qRT-PCR                     median                                  OS/DFS                       SC                       180
  Wotschofsky,2012          Germany              R            renal cell carcinoma        111     T1--T4      qRT-PCR                     median                                    OS                      reported              8.0 (3.4--44.8)
  Zaravinos, 2012           Greece               R               bladder cancer            77       --        qRT-PCR                     median                                    OS                      reported                     50

Study design is described as consecutive patients (C), prospective (P) or retrospective (R). --, not reported; HNSCC, head and neck squamous cell carcinomas; PDAC, pancreatic ductal adenocarcinoma; qRT-PCR, quantitative real-time PCR; OS, overall survival; DSS, disease-specific survival; DFS, disease-free survival; RFS, relapse-free survival; PFS, Progression-free survival; AP, author provided; DE, data-extrapolated; SC, survival curve.

\*the OS data is obviously not consistent with the survival curves, so only provided DFS is used for analysis.

10.1371/journal.pone.0089223.t002

###### Summary table of HRs and their 95% CI.

![](pone.0089223.t002){#pone-0089223-t002-2}

  study          year              Disease               HR       95% CI and P value      outcome
  ------------- ------ ------------------------------- ------- ------------------------- ---------
  Madhavan       2012     metastatic breast Cancer      0.31    0.09--1.02, P = 0.00023     OS
  Zaravinos      2012          bladder cancer           0.34      0.11--1, P = 0.049        OS
  Wotschofsky    2012       renal cell carcinoma        0.39     0.12--1.23, P = 0.109      OS
  Geither        2012        soft-tissue sarcoma         0.5     0.23--1.12, P = 0.084      OS
  Markou         2013           breast cancer           1.028   0.486--2.174, P = 0.943     OS
  Markou         2013           breast cancer           1.049   0.581--1.895, P = 0.873     DFS
  Neal           2010           renal cancer            1.15     0.15--8.65, P = 0.189      OS
  Madhavan       2012     metastatic breast Cancer      1.18     0.84--1.67, P = 0.107      PFS
  Qiu            2013           Glioblastoma            1.19    1.02--1.37, P = 0.0212      PFS
  Qiu            2013           Glioblastoma            1.33    1.13--1.57, P = 0.0077      OS
  Volinia        2012           breast cancer           1.41     0.32--6.16, P = 0.013      DFS
  Gee            2009           primary HNSCC           1.49    0.22--10.09, P = 0.008      OS
  Volinia        2012           breast cancer           1.57     0.38--6.52, P = 0.006      OS
  Gee            2009           primary HNSCC           1.58    0.12--19.93, P = 0.003      DFS
  Radojicic      2011           breast cancer             2     0.29--13.75, P = 0.1220     OS
  Geither        2009               PDAC                2.48     1.32--4.68, P = 0.005      OS
  Geither        2009               PDAC                 2.5     1.24--5.02, P = 0.01       DFS
  Cai            2013      pediatric osteosarcoma        2.6      0.8--7.2, P = 0.02        PFS
  McCormick      2012           renal cancer            3.01     1.39--6.51, P = 0.005      OS
  Cai            2013      pediatric osteosarcoma        3.3       1--8.2, P = 0.01         OS
  Radojicic      2011           breast cancer           3.72    0.75--18.75, P = 0.0658     DFS
  Camps          2008           breast cancer           4.07     1.7--9.75, P = 0.002       DFS
  Toyama         2012   Triple-negative Breast cancer   4.39      1--19.28, P = 0.036       RFS
  Rothe          2011           breast cancer           4.43    1.91--10.16, P = 0.0005     RFS
  Camps          2008           breast cancer           11.38    4.1--31.65, P\<0.001       OS

10.1371/journal.pone.0089223.t003

###### Summary table of the miRNA detection and HR calculation.

![](pone.0089223.t003){#pone-0089223-t003-3}

  study          year      internal reference           miR-210 expression             risk evaluation method
  ------------- ------ --------------------------- ---------------------------- ------------------------------------
  Madhavan       2012          cel-miR-39                 5.17, P\<0.05                     Kaplan-Meier
  Zaravinos      2012     RNU1A1, RNU5A, RNU6B           ∼1.3, P = 0.4554              Univariate regression
  Wotschofsky    2012   miR-28, miR-103, miR-106a       ∼0.63, P = 0.0.193             Univariate regression
  Geither        2012              U18                   127.851--870.550        Mul Cox proportional harzard model
  Markou         2013            miR-191                  --, P = 0.708                     Kaplan-Meier
  Neal           2010         RNU43, RNU48                 8, P = 0.05                      Kaplan-Meier
  Qiu            2013              --                           --                          Kaplan-Meier
  Volinia        2012              --                           --                          Kaplan-Meier
  Gee            2009      RNU43, RNU44, RNU48      2.02(0.15--8.18), P\>0.05               Kaplan-Meier
  Geither        2009           18S rRNA               0.31 (0.006--122.9)       Mul Cox proportional harzard model
  Cai            2013             RNU6B                  ∼1.15, P\<0.001                    Kaplan-Meier
  McCormick      2012      RNU44, RNU48, RNU6B             10, P\<0.001                     Kaplan-Meier
  Radojicic      2011         RNU5A, RNU6B             3.74±4.01, P\<0.001                  Kaplan-Meier
  Camps          2008             RNU43             5.48(0.08--67.81), P\<0.05   Mul Cox proportional harzard model
  Toyama         2012             RNU6B                11.1±2.60, P\<0.001       Mul Cox proportional harzard model
  Rothe          2011         RNU44, RNU48               ∼3.43, P = 0.009                   Kaplan-Meier

Meta-analysis Results {#s3b}
---------------------

For studies evaluating OS of patients, a pooled HR and its 95% CI were calculated with a random model because of the high heterogeneity between studies (*P*  = 0.000, I^2^ = 74.0%). The result showed that higher expression of miR-210 may predict poor OS, and the pooled HR was 1.33 (95% CI: 0.85--2.09) ([Fig. 2a](#pone-0089223-g002){ref-type="fig"}), however, the effect did not reach the level of statistical significance (*P* = 0.210). As the studies testing DFS were not of obvious heterogeneity (*P*  = 0.144, I^2^ = 39.3%), we used a fixed model to pool the HRs, and the pooled HR 1.89 (95% CI: 1.30--2.74) ([Fig. 2b](#pone-0089223-g002){ref-type="fig"}) revealed that over-expression of miR-210 significantly predicted poor DFS (*P* = 0.001). For articles reporting PFS (n = 3) and RFS (n = 2) as their outcome assessments, the results of heterogeneity tests were *P*  = 0.382 and I^2^ = 0.0%, and *P*  = 0.992 and I^2^ = 0.0% respectively. Therefore, a fixed model was used to calculate the pooled HR, and the pooled HR for PFS was 1.20 (95% CI: 1.05--1.38, *P* = 0.007) ([Fig. 2b](#pone-0089223-g002){ref-type="fig"}) and 4.42 for RFS (95% CI: 2.14--9.15, *P* = 0.000) ([Fig. 2b](#pone-0089223-g002){ref-type="fig"}), indicating that high level of miR-210 expression was related to poor PFS, and even worse to RFS.

![Forrest plotsof studies evaluating hazard ratios of high miR-210 expression.\
(A) Overall survival test. The survival data from 14 records were pooled to calculate overall survival. The random effects analysis model showed the pooled HR for overall survival is 1.33 with 95% CI 0.85--2.09, and *P* value is 0.210. (B) Survival data were presented as disease-free survival, relapse-free survival and progression-free survival. The fix effect analysis model was used to calculate the pooled HRs, and the results were HR = 1.89 (95%CI: 1.30--2.74, *P* = 0.001) for DFS, HR = 4.42 (95%CI: 2.14--9.15, *P* = 0.000) for RFS, and HR = 1.20 (95%CI: 1.05--1.38, *P* = 0.007) for PFS.](pone.0089223.g002){#pone-0089223-g002}

We also carried out subgroup analysis in breast cancer, renal cancer and sarcoma. Firstly, the HRs for OS (n = 5) and DFS (n = 4) in articles involving breast cancer were pooled. As an obvious heterogeneity (*P* = 0.000 and I^2^ = 82.3%) existed in these researches of OS, a random model was used to pool the HRs. The combined HR, 1.63 (95% CI: 0.47--5.67, *P* = 0.443) ([Fig. S1](#pone.0089223.s001){ref-type="supplementary-material"}) indicated that over-expressed miR-210 would not precisely predict poor OS for patients with breast cancer. We used a random model to calculate the combined HR for DFS, as there was heterogeneity (*P* = 0.061 and I^2^ = 59.3%). The pooled HR 2.03 (95% CI: 0.90--4.57, *P* = 0.088) ([Fig. S2](#pone.0089223.s002){ref-type="supplementary-material"}) showed miR-210 was a potential predictor of poor DFS in breast cancer. In the 3 articles about renal cancer using OS to assess outcome, the heterogeneity was significant (*P* = 0.016 and I^2^ = 76.0%), and the random model calculation produced the combined HR as 1.16 (95% CI: 0.27--4.94, *P* = 0.842) [Fig. S1](#pone.0089223.s001){ref-type="supplementary-material"}), implying the association between over-expressed miR-210 and poor OS was not significant in renal cancer. High heterogeneity (*P*  = 0.005 and I^2^ = 87.3%) was confirmed in 2 reports using OS as sarcoma outcome assessment value, and the combined HR reached 1.24 (95% CI: 0.20--7.89, *P* = 0.818) ([Fig. S2](#pone.0089223.s002){ref-type="supplementary-material"}) by calculating with a random model. Therefore, the over-expressed miR-210 may not exactly predict poor outcome of sarcoma patients.

Heterogeneity Analysis Results {#s3c}
------------------------------

Obvious heterogeneity of subjects was found in 5 of the 8 analysis groups (OS for all, *P*\<0.05, I^2^ = 72.0%; OS for breast cancer, *P* = 0.000 and I^2^ = 82.3%; OS for renal cancer, *P* = 0.016 and I^2^ = 76.0%; DFS for breast cancer, *P* = 0.061 and I^2^ = 59.3%, and OS for sarcoma, P = 0.005 and I^2^ = 87.3%). The most possible sources of heterogeneity were also analyzed by different methods. On one hand, since the heterogeneity of OS analysis group (14 studies) was obvious (*P*\<0.05 and I^2^ = 72.0%), we divided the 14 studies into 3 cancer type-specific analysis groups (5 studies on breast cancer, 3 studies for renal cancer and 2 studies on sarcoma). The heterogeneity was still obvious in the 3sub-groups, so the cancer type could not solely explain the heterogeneity in OS analysis group. On the other hand, we conducted a meta regression to evaluate the potential factors responsible for the obvious heterogeneity. As a result, the publication year (*P* = 0.075), cut-off values (*P* = 0.228), patients origin (*P* = 0.252), risk evaluation method (*P* = 0.275), follow-up time (*P* = 0.280), cancer type (*P* = 0.453), sample size (*P* = 0.944) contributed to the heterogeneity to one degree or another. For the groups with less than 10 studies (meta regression is not proper to seek the sources of heterogeneity), we performed sensitivity analysis. In the OS analysis group for breast cancer, heterogeneity was significant (*P* = 0.000 and I^2^ = 82.3%). When Camps' study was removed from analysis, the heterogeneity became insignificant (*P* = 0.228 and I^2^ = 30.7%). Therefore, we got a conclusion that Camps' study was responsible for the heterogeneity. In another 2 analysis groups, Camps', Wotschofsky's study were responsible for the heterogeneity of DFS analysis group for breast cancer and OS analysis group for renal cancer respectively.

Publication Bias {#s3d}
----------------

Finally, the publication bias of included studies was evaluated by funnel plots and Egger's tests. As shown in [Fig. 3](#pone-0089223-g003){ref-type="fig"}, the funnel plots were almost symmetric. In OS, DFS and PFS meta-analysis, the *P* values of Egger's regression intercepts were 0.973, 0.578 and 0.378, respectively. Hence, there was no evidence for significant publication bias in our meta-analysis.

![Funnel plots of studies included in the three meta-analysis: (A) overall survival, (B) disease-free survival and (C) progress-free survival.](pone.0089223.g003){#pone-0089223-g003}

Discussion {#s4}
==========

MiR-210 is an extensively studied hypoxia-related miRNA while hypoxia is an important pathophysiological process in solid cancer. Researches revealed that the expression of miR-210 was elevated in a variety of solid tumors, including breast cancer, non-small cell lung cancer, head and neck cancer, pancreatic cancer, oral tumors, hepatocellular cancer (HCC), adrenocortical carcinoma (ACC), colon cancer, ovarian cancer, glioblastoma, malignant melanoma and renal cell cancer. However, the down-regulation of miR-210 in human esophageal squamous cell carcinoma (ESCC) tissues and the derived cell lines was also reported [@pone.0089223-Tsuchiya1], [@pone.0089223-Hong1], [@pone.0089223-Yang1], [@pone.0089223-Zang1].

Transcriptionally regulated by hypoxia-induced factor (HIF), miR-210 controls the cellular response to hypoxia [@pone.0089223-Chan1] and, in a way, helps cells adapt to hypoxia. Hypoxia-driven miR-210 directly targets E2F3 to inhibit cell proliferation in various cell lines including keratinocytes, ovarian cancer cells and human embryonic kidney cells [@pone.0089223-Giannakakis1], [@pone.0089223-Biswas1], [@pone.0089223-Nakada1]. E2F3 could promote cell proliferation by allowing cell cycle progression from G1 to S phase and the initiation of DNA replication [@pone.0089223-Dirks1], [@pone.0089223-Leone1], [@pone.0089223-Vigo1]. Researches in cancer tissues and cells [@pone.0089223-Biswas1], [@pone.0089223-Nakada1] have proved miR-210 could inhibit cell proliferation via a fibroblast growth factor receptor (FGFR)-like 1 (FGFRL1) dependent mechanism since FGFRL1 promotes cell proliferation by facilitating cell cycle progression. Homeobox A1 (HOXA1) is also a target of miR-210, and over-expression of HOXA1 not only induced the activation of p44/42 MAP kinase to support cell proliferation but also reversed the inhibitory effect of miR-210 on cell growth. So, miR-210 could inhibit cell proliferation via targeting HOXA1 [@pone.0089223-Huang1], [@pone.0089223-Mohankumar1]. However, over expressed miR-210 could inhibit cell death, promote cell survival by suppressing BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) in neural progenitor cells (NPC) [@pone.0089223-Wang1]. Elevated miR-210 expression could also increase survival rates along with Akt and ERK activity in human mesenchymal stem cells (hMSCs) with hypoxia [@pone.0089223-Chang1]. In addition, miR-210 is found to be one of the components responsible for radioresistance in human lung cancer cell lines H1975 [@pone.0089223-Grosso1]. What We should also noticed is that, by targeting MNT, a MYC antagonist, miR-210 promotes cell cycle progression in transformed cells such as colon cancer cells and cervical cancer cells [@pone.0089223-Zhang1]. This contradiction suggests a cell context-oriented effect of miR-210, and is supported by our data as the HRs varied with different cancer types.

MiR-210 depresses mitochondrial metabolism by targeting iron--sulfur cluster assembly homologue 1/2 (ISCU 1/2), which catalyzes the assembly of \[4Fe-4S\] and \[2Fe-2S\] Fe-S clusters to support mitochondrial functions [@pone.0089223-Rouault1], [@pone.0089223-Chen1]. Besides, cytochrome oxidase assembly protein-10 (COX-10) and succinate dehydrogenase subunit D (SDHD) are all targets of miR-210 [@pone.0089223-Chen1], [@pone.0089223-Puissegur1]. So miR-210 may be a potent inhibitor in mitochondrial respiration by targeting TCA cycle and electron transport chain activity, and this down-tuning of glucose oxidation may decrease the harm of hypoxia, a condition inducing angiogenesis in solid tumors. On the other hand, over expressed miR-210 contributes to angiogenesis after cerebral ischemia by activating the Notch signaling pathway [@pone.0089223-Lou1], while miR-210 inhibitor abrogates and 210 mimic recapitulates the pro-angiogenic effects by VEGF treatment in post-expansion CD34+ cells [@pone.0089223-Alaiti1].

MiR-210 was recently reported to stall DNA repair by directly binding to the 3′ UTR of RAD52 [@pone.0089223-Crosby1], a protein that fixes DNA double-strand break, repairs single-stranded DNA gaps and facilitates RAD51-mediated strand invasion during homologous recombination [@pone.0089223-Mortensen1], [@pone.0089223-West1]. On the other hand, miR-210 promotes angiogenesis by inhibiting ephrin A3 (EFNA3) [@pone.0089223-Fasanaro1], [@pone.0089223-Hu1], or directly targeting on protein-tyrosine phosphatase 1B (PTP1B) [@pone.0089223-Hu1], [@pone.0089223-Fasanaro2]. Bianchi et al. reported a DNA-binding drug, mithramycin, promotes erythroid differentiation, induced the expression of miR-210 in erythroid progenitor cells [@pone.0089223-Bianchi1]. Another report [@pone.0089223-Mizuno1] showed miR-210 promotes bone morphogenic protein (BMP)-induced osteoblastic differentiation via targeting ACVR1B. In addition, miR-210 supports stem cell survival under hypoxia condition was demonstrated [@pone.0089223-Kim1].

Up to now, the lab experimental results reveal that miR-210 may be essential for cancer cells to survival. In this meta-analysis, we got 8 pooled HRs from 1697 patients with 7 different cancers reported by 15 researches from 7 countries. In conclusion, the over-expression of miR-210 did predict poor survival of patients with cancers. Our analysis result was consistent with a previous meta-analysis [@pone.0089223-Kopriva1] about miR-210 expression level and breast cancer patient survival. In the previous analysis, a pooled HR of the OS from only 4 records was 3.39 (95% CI: 2.04--5.63, *P*\<0.05) for breast cancers, but the author wrongly assigned the HR for RFS to HR for OS in Toyama's research [@pone.0089223-Toyama1].

Although the predictive effect of miR-210 was statistically proved, it should be carefully understood for following reasons. First, though the combined HR for OS was 1.62, considering its Pvalue 0.05, the predictive effect was not very strong. While the HRs of DFS, PFS, RFS, DFS for breast cancer and OS for sarcoma varied from 1.20 to 4.42 with all P values \<0.015, but the numbers of researches for calculating HRs were all ≤5. Second, we only included articles in English, strictly, this might result in the miss of eligible researches published in other languages. Third, several HRs were calculated based on the data extracted from the survival curve, and this may bring errors although tiny. Fourth, we pooled HRs from different articles with different cut-off values due to methods limitations. We could not set up a baseline refering to miR-210 high expression either. The information of the included studies revealed that the heterogeneity could be attributed to the differences in the publication years, the types and stages of the cancers, the sample sizes, the cut-off values of miR-210, the durations of follow-up and the risk evaluation methods. We conducted sub-group analysis, meta regression and sensitive analysis to find out the possible sources of heterogeneity. So these factors and studies should be paid more attention to when the concerning conclusions were taken under consideration. Because differences might have a residual confounding effect within the relative studies, we attempted to minimize the effect by using a random effect model. Furthermore, although no significant publication bias was detected in the meta-analysis, the records size was not large enough to ensure the conclusion. Two researches [@pone.0089223-Camps1], [@pone.0089223-Madhavan1] about breast cancer collected their samples from patients after a period of treatment, 3 researches on HNSCC, breast cancer, bladder cancer [@pone.0089223-Gee1], [@pone.0089223-Rothe1], [@pone.0089223-Zaravinos1] emphasized that their samples were got from untreated patients, while the rest 11 researches [@pone.0089223-Toyama1], [@pone.0089223-Qiu1], [@pone.0089223-McCormick1], [@pone.0089223-Greither1], [@pone.0089223-Volinia1], [@pone.0089223-Greither2], [@pone.0089223-Neal1], [@pone.0089223-Radojicic1], [@pone.0089223-Cai1], [@pone.0089223-Wotschofsky2], [@pone.0089223-Markou1] did not exactly mention this issue. Theoretically, treatments may influence the expression of miR-210 in cancer samples, however, none of the researches referred to the treatment effect on HRs or miR-210 expression, and no conclusion could be drawn according to current data.

To date, miRNAs have been widely considered as oncogene/cancer suppressor, nevertheless, several concerns should be stressed. (i) Oncogenesis was a complicated process in our bodies involving numerous molecular pathways, and considering this, a set of miRNAs may more accurately represent cancer prognosis. (ii) Lacking of systemic standard of miRNAs or a standard reference miRNA made it difficult to explore their clinical application. For example, in the included researches, different cut-off values were used to stratify miR-210 expression levels. It is unclear whether each cancer type owns its specific cut-off value of individual miRNA, or shares the same cut-off value with others. (iii) Although several researches had reported the potential roles of miRNAs in chemo/radiation therapy [@pone.0089223-Kheirelseid1], [@pone.0089223-Gaca1], [@pone.0089223-DellaVittoriaScarpati1], the efficiency and feasibility of miRNA therapies, such as interfering the expression of a specific miRNA or a set of them, and evaluating the side effect, still need to be investigated. (iv) Most of the included researches detected miRNA expression in cancer tissue samples, and that certainly matched the current clinical idea of golden standard for deterministic diagnosis. A simultaneous detection of miRNA in serum may give more information about host response and the prognosis although cancer tissue samples represent the condition of cancer tissue more appropriately than serum samples do.

Conclusion {#s5}
==========

This meta-analysis summarized the global researches on the relationship of aberrant miR-210 expression and cancer patient survival, and clarified that over-expression of miR-210 in several cancers does predict poor survival of patients. Given the limitation of the current analysis, it should be cautious to appreciate the conclusion, and further clinical investigations are needed to testify the association between miR-210 and cancer prognosis as well as the efficiency of therapies.

Supporting Information {#s6}
======================

###### 

**Subgroup analysis: Forrest plots of studies evaluating hazard ratios of high miR-210 expression as compared to low expression in subgroup analysis.** The random effect model is used to pool the HRs. As to overall survival for breast cancer, HR = 1.63 (95%CI: 0.47--5.67, *P* = 0.443), overall survival for renal cancer, HR = 1.16 (95%CI: 0.27--4.94, *P* = 0.842).

(TIF)

###### 

Click here for additional data file.

###### 

**Subgroup analysis: Forrest plots of studies evaluating hazard ratios of high miR-210 expression as compared to low expression in subgroup analysis.** The random effect model is used to pool the HRs. As to overall survival for sarcoma, HR = 1.24 (95%CI: 0.20--7.89, P = 0.818), disease-free survival for breast cancer, HR = 2.03 (95%CI: 0.90--4.57, P = 0.088).

(TIF)

###### 

Click here for additional data file.

###### 

**Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2009 Checklist.**

(DOC)

###### 

Click here for additional data file.

###### 

**Meta-analysis of Observational Studies in Epidemiology group (MOOSE) Checklist.**

(DOC)

###### 

Click here for additional data file.
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